FERNANDO REIS MENEZES

Índice h a partir de 2011
2
ResearcherID
Projetos de Pesquisa
Unidades Organizacionais

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 10 de 24
  • conferenceObject
    Is there a Correlation Between Bleeding Risk Score and Platelet Aggregability?
    (2014) ARANTES, Flavia B.; FURTADO, Remo H.; BARBOSA, Carlos J.; FRANCI, Andre; MENEZES, Fernando R.; FALCAO, Talia D.; NAKASHIMA, Carlos A.; BARACIOLI, Luciano M.; RAMIRES, Jose A.; NICOLAU, Jose C.
  • conferenceObject
    EFFECT OF TICAGRELOR AND CLOPIDOGREL ON CORONARY MICROCIRCULATION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
    (2019) SCANAVINI FILHO, Marco Antonio; BERWANGER, Otavio; MATHIAS JUNIOR, Wilson; AGUIAR, Miguel Osman; CHIANG, Hsu Po; BARACIOLI, Luciano Moreira; LIMA, Felipe Gallego; MENEZES, Fernando Reis; DALCOQUIO, Talia; FURTADO, Remo Holanda M.; LUCA, Fabio Augusto De; UEZATO, Delcio; RAMIRES, Jose Antonio Franchini; KALIL FILHO, Roberto; NICOLAU, Jose Carlos
  • bookPart
    Indicação e manejo de balão intra-aórtico e suporte cardiocirculatório
    (2016) MENEZES, Fernando Reis; FURTADO, Remo Holanda de Mendonça; BARACIOLI, Luciano Moreira
  • conferenceObject
    Do women have worse response to P2Y12 antagonists than men after acute coronary syndrome?
    (2016) NICOLAU, J. C.; FERRARI, A. G.; DALCOQUIO, T.; FURTADO, R. H. M.; SCANAVINI, M. A.; NAKASHIMA, C. A. K.; ARANTES, F. B. B.; MENEZES, F. R.; LIMA, F. G.; BARACIOLI, L. M.; STRUNZ, C. M. C.; RAMIRES, J. A. F.; KALIL, R.
  • bookPart
    Monitorização clínica e hemodinâmica em síndromes coronárias agudas
    (2016) FURTADO, Remo Holanda de Mendonça; MENEZES, Fernando Reis; BARACIOLI, Luciano Moreira
  • conferenceObject
    SAFETY AND EFFICACY OF DPP4 INHIBITORS IN ACUTE MYOCARDIAL INFARCTION: A BIOMARKER DRIVEN DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL
    (2021) GENESTRETI, Paulo Rizzo; FURTADO, Remo; SALSOSO, Rocio; DALCOQUIO, Talia; NAKASHIMA, Carlos; LIMA, Viviane; COLODETTI, Raiza; FERRARI, Aline; FRANCI, Andre; MENEZES, Fernando; BARACIOLI, Luciano; NICOLAU, Jose
  • conferenceObject
    INCREASED BODYWEIGHT AND INADEQUATE RESPONSE TO ASPIRIN IN INDIVIDUALS WITH CORONARY ARTERY DISEASE
    (2019) FURTADO, Remo Holanda de Mendonca; ARANTES, Flavia; BARBOSA, Carlos; FRANCI, Andre; MENEZES, Fernando; SALSOSO, Rocio; DALCOQUIO, Talia; NAKASHIMA, Carlos; SCANAVINI FILHO, Marco; FERRARI, Aline; GENESTRETI, Paulo; BARACIOLI, Luciano; NICOLAU, Jose C.
  • article 5 Citação(ões) na Scopus
    Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial
    (2020) ARANTES, Flavia B. B.; MENEZES, Fernando R.; FRANCI, Andre; BARBOSA, Carlos J. D. G.; DALCOQUIO, Talia F.; NAKASHIMA, Carlos A. K.; BARACIOLI, Luciano M.; FURTADO, Remo H. M.; NOMELINI, Quintiliano S. S.; RAMIRES, Jose A. F.; KALIL FILHO, Roberto; NICOLAU, Jose C.
    Introduction The interaction between anticoagulants and platelet function is complex. Previous publications showed mixed results regarding the role of heparins in platelet aggregation. On the other hand, the direct thrombin inhibitor (DTI) dabigatran might enhance the risk of myocardial infarction in patients with atrial fibrillation, which could be related to increased platelet aggregability. Methods This was a prospective, interventional study of patients with chronic coronary artery disease (CAD) taking low-dose aspirin. The objective of the current study was to compare the effects of dabigatran versus enoxaparin on platelet aggregability. Subjects initially were on orally administered dabigatran for 5 days followed by subcutaneously administered enoxaparin after a 30-day washout period. Platelet function was assessed at baseline and after each intervention by multiple electrode aggregometry (MEA-ASPI) (primary endpoint), serum thromboxane B2 (TXB2), VerifyNow Aspirin (TM), and coagulation tests (secondary endpoints). Results Compared to baseline MEA-ASPI values, dabigatran increased platelet aggregation while enoxaparin decreased platelet aggregation (+ 5 U +/- 24.1 vs - 6 U +/- 22.2, respectively, p = 0.012). The TXB2 assay showed the same pattern (+ 2 pg/ml for dabigatran vs - 13 pg/ml for enoxaparin, p = 0.011). None of the additional tests showed significant differences between the groups. Individually, compared to baseline TXB2 results, enoxaparin significantly decreased platelet activation [33 (16.5-95) pg/mL vs 20 (10-52) pg/mL, respectively, p = 0.026], but no significant differences were observed with dabigatran. Conclusions DTI and anti-Xa drugs exert opposite effects on platelet function. A significant decrease in platelet activation through COX1 (also known as prostaglandin G/H synthase 1) was observed with enoxaparin, but no significant differences in platelet function were observed with dabigatran.
  • conferenceObject
    THE ROLE OF ORAL BETA BLOCKER IN A REAL-WORLD POPULATION WITH NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROMES
    (2017) NICOLAU, Jose C.; FERRARI, Aline; COELHO, Gabriela M. M.; NAKASHIMA, Carlos A. K.; LIMA, Viviane M.; DALCOQUIO, Talia; FURTADO, Remo; MENEZES, Fernando; RAMIRES, Jose; KALIL-FILHO, Roberto; BARACIOLI, Luciano
  • bookPart
    Choque cardiogênico pós-infarto agudo do miocárdio
    (2018) MENEZES, Fernando Reis; PAOLINO, Bruno de Souza; GANEM, Fernando